Chiasma, Inc.

Crinetics Pharmaceuticals, Inc. ’s paltusotine succeeded in the first of two Phase III clinical trials in acromegaly, showing that patients switching from standard-of-care monthly injectable somatosta

The European Medicines Agency has begun reviewing a number of new medicines for potential pan-EU marketing approval, including lenacapavir, Gilead Sciences ’ investigational, first-in-class, long-act

Ahead of an imminent US regulatory decision on the butterfly skin drug Filsuvez, Amryt Pharma has been telling analysts about its plans to deliver group revenues of $1bn in the coming years. The Iri

The European Medicines Agency has begun reviewing a number of new medicines for potential pan-EU marketing authorization, including three investigational orphan drugs –Nefecon (budesonide), maribavir